These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

16 related articles for article (PubMed ID: 38995699)

  • 1. Lupus nephritis-related chronic kidney disease.
    Lichtnekert J; Anders HJ
    Nat Rev Rheumatol; 2024 Sep; ():. PubMed ID: 39317803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
    Heerspink HJL; Kiyosue A; Wheeler DC; Lin M; Wijkmark E; Carlson G; Mercier AK; Åstrand M; Ueckert S; Greasley PJ; Ambery P
    Lancet; 2023 Nov; 402(10416):2004-2017. PubMed ID: 37931629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
    Heerspink HJL; Greasley PJ; Ahlström C; Althage M; Dwyer JP; Law G; Wijkmark E; Lin M; Mercier AK; Sunnåker M; Turton M; Wheeler DC; Ambery P
    Nephrol Dial Transplant; 2024 Feb; 39(3):414-425. PubMed ID: 37632201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.
    Veenit V; Heerspink HJL; Ahlström C; Greasley PJ; Skritic S; van Zuydam N; Kohan DE; Hansen PBL; Menzies RI
    Nephrol Dial Transplant; 2023 Sep; 38(10):2289-2297. PubMed ID: 37102226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials.
    Mercier AK; Ueckert S; Sunnåker M; Hamrén B; Ambery P; Greasley PJ; Åstrand M
    Clin Pharmacol Ther; 2024 Sep; 116(3):653-664. PubMed ID: 38961664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
    Natale P; Tunnicliffe DJ; Toyama T; Palmer SC; Saglimbene VM; Ruospo M; Gargano L; Stallone G; Gesualdo L; Strippoli GF
    Cochrane Database Syst Rev; 2024 May; 5(5):CD015588. PubMed ID: 38770818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis.
    McEwan P; Hafner M; Jha V; Correa-Rotter R; Chernin G; De Nicola L; Villanueva R; Wheeler DC; Barone S; Nolan S; Garcia Sanchez JJ
    J Med Econ; 2023; 26(1):1407-1416. PubMed ID: 37807895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I
    Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.